Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13563-13572
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13563
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13563
Table 1 An analysis of the general baseline conditions of the patients in each group
Group 1 | Group 2 | Group 3 | Group 4 | P value | |
n | 40 | 40 | 40 | 40 | |
Age (yr) | 55 | 46.5 | 51.5 | 52 | 0.196 |
Gender | 0.330 | ||||
Male | 42.5% | 45% | 42.5% | 45% | |
Female | 57.5% | 55% | 57.5% | 55% | |
Disease duration (yr) | 3 | 5 | 4 | 5 | 0.300 |
Disease severity scores | 231.7 ± 68.0 | 221.5 ± 79.2 | 233.3 ± 73.9 | 241.5 ± 79.3 | 0.698 |
Table 2 Comparisons of the symptom scores for patients in each group at different stages of treatment
Group | n | Birmingham | IBS-QOL | SDS | SAS | HAMD | HAMA | |
Group 1 | 40 | Before | 21.10 ± 8.62 | 75.75 ± 21.72 | 45.33 ± 11.04 | 42.83 ± 9.62 | 6.13 ± 5.43 | 5.90 ± 5.22 |
1st course | 11.60 ± 7.53a | 60.20 ± 14.82a | 36.20 ± 8.37a | 36.65 ± 9.37a | 3.75 ± 3.40a | 4.05 ± 3.57a | ||
2nd course | 5.55 ± 5.05abc | 50.65 ± 10.86ab | 32.43 ± 6.94ab | 32.08 ± 6.95ab | 1.75 ± 2.31ab | 2.23 ± 2.90ab | ||
Group 2 | 40 | Before | 23.45 ± 8.25 | 75.38 ± 21.02 | 43.45 ± 13.93 | 43.10 ± 12.86 | 7.25 ± 7.06 | 6.68 ± 4.74 |
1st course | 15.58 ± 9.15a | 59.40 ± 18.02a | 38.13 ± 10.54a | 37.35 ± 10.03a | 4.03 ± 3.28a | 3.28 ± 3.03a | ||
2nd course | 10.45 ± 6.61ab | 47.90 ± 10.49ab | 32.53 ± 7.26ab | 32.25 ± 7.14ab | 1.98 ± 2.38ab | 1.93 ± 2.14ab | ||
Group 3 | 40 | Before | 21.50 ± 8.82 | 78.53 ± 24.22 | 46.80 ± 13.53 | 46.15 ± 12.74 | 9.05 ± 6.54 | 7.53 ± 5.37 |
1st course | 13.03 ± 8.23a | 58.28 ± 13.39a | 38.40 ± 10.41a | 37.95 ± 8.65a | 4.60 ± 2.77a | 3.98 ± 2.30a | ||
2nd course | 5.65 ± 4.00abc | 48.83 ± 9.38ab | 32.50 ± 7.95ab | 33.70 ± 7.00ab | 2.10 ± 1.95ab | 2.20 ± 1.60ab | ||
Group 4 | 40 | Before | 23.65 ± 7.62 | 76.88 ± 19.90 | 46.00 ± 12.59 | 44.38 ± 12.02 | 7.50 ± 7.66 | 6.63 ± 4.78 |
1st course | 13.95 ± 7.69a | 60.00 ± 16.09a | 38.15 ± 9.76a | 37.23 ± 10.50a | 4.10 ± 4.89a | 3.68 ± 2.67a | ||
2nd course | 8.38 ± 6.17ab | 48.48 ± 13.87ab | 32.38 ± 9.15ab | 33.45 ± 8.73ab | 1.90 ± 3.04ab | 2.20 ± 2.39ab |
Table 3 Comparisons of the degrees of improvement in symptoms and relevant scales for patients in each group at different stages of treatment
Frequency | P value | |||||||
Scale | n | Cone | Three treatments/wk | Six treatments/wk | Cone | Frequency | Conefrequency | |
Birmingham | 40 | 1 | 42.24 ± 36.12 | 35.20 ± 23.84 | 0.643 | 0.845 | 0.254 | |
40 | 2 | 30.30 ± 77.95 | 40.25 ± 29.15 | |||||
IBS-QOL | 40 | 1 | 17.40 ± 19.04 | 20.25 ± 14.37 | 0.255 | 0.847 | 0.348 | |
40 | 2 | 22.63 ± 15.67 | 20.76 ± 13.83 | |||||
SDS | 40 | 1 | 17.99 ± 17.02 | 10.49 ± 9.66 | 0.734 | 0.133 | 0.140 | |
1st course | 40 | 2 | 15.13 ± 19.32 | 15.06 ± 15.81 | ||||
SAS | 40 | 1 | 13.72 ± 13.53 | 11.96 ± 9.97 | 0.279 | 0.535 | 0.849 | |
40 | 2 | 15.65 ± 13.50 | 14.72 ± 16.67 | |||||
HAMD | 40 | 1 | 27.69 ± 48.61 | 39.54 ± 32.69 | 0.347 | 0.071 | 0.987 | |
40 | 2 | 33.78 ± 40.44 | 45.84 ± 42.93 | |||||
HAMA | 40 | 1 | 12.04 ± 65.36 | 46.90 ± 28.61 | 0.458 | 0.011 | 0.028 | |
40 | 2 | 33.62 ± 44.65 | 36.19 ± 37.95 | |||||
Birmingham | 40 | 1 | 73.74 ± 19.43 | 56.19 ± 21.62 | 0.393 | 0.002 | 0.078 | |
40 | 2 | 70.46 ± 27.24 | 65.56 ± 20.91 | |||||
IBS-QOL | 40 | 1 | 29.98 ± 16.59 | 34.26 ± 13.63 | 0.247 | 0.208 | 0.562 | |
40 | 2 | 34.02 ± 15.29 | 35.60 ± 12.88 | |||||
SDS | 40 | 1 | 26.12 ± 16.15 | 21.65 ± 14.35 | 0.149 | 0.373 | 0.373 | |
2nd course | 40 | 2 | 27.51 ± 17.52 | 27.51 ± 15.12 | ||||
SAS | 40 | 1 | 23.68 ± 12.83 | 22.54 ± 12.14 | 0.871 | 0.604 | 0.996 | |
40 | 2 | 24.02 ± 15.77 | 22.90 ± 13.81 | |||||
HAMD | 40 | 1 | 63.06 ± 36.74 | 68.88 ± 32.05 | 0.139 | 0.182 | 0.845 | |
40 | 2 | 69.63 ± 30.35 | 77.45 ± 29.05 | |||||
HAMA | 40 | 1 | 49.62 ± 46.44 | 62.61 ± 38.66 | 0.502 | 0.238 | 0.450 | |
40 | 2 | 59.19 ± 49.29 | 62.04 ± 32.62 |
Table 4 Correlation analysis of the degrees of improvements in relevant scales and the degrees of symptom improvement
Group | n | Degrees of symptom improvement(Birmingham) | Degrees of improvements inrelevant scales | r | P value | |
Aconite cake-separated moxibustion groups | 160 | 66.49 ± 23.25 | IBS-QOL | 33.46 ± 14.68 | 0.080 | 0.317 |
SDS | 25.70 ± 15.87 | 0.165 | 0.037 | |||
SAS | 23.28 ± 13.59 | 0.161 | 0.042 | |||
HAMD | 69.75 ± 32.28 | 0.088 | 0.276 | |||
HAMA | 58.36 ± 42.19 | 0.331 | 0.077 |
- Citation: Zhao JM, Wu LY, Liu HR, Hu HY, Wang JY, Huang RJ, Shi Y, Tao SP, Gao Q, Zhou CL, Qi L, Ma XP, Wu HG. Factorial study of moxibustion in treatment of diarrhea-predominant irritable bowel syndrome. World J Gastroenterol 2014; 20(37): 13563-13572
- URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13563.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13563